Hit-to-lead optimization of pyrrolo[1,2-a]quinoxalines as novel cannabinoid type 1 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 13, 2009, Pages 3471-3475

  Szabó, György ^a   Kiss, Róbert ^a,b   Páyer Lengyel, Dóra ^a   Vukics, Krisztina ^a   Szikra, Judit ^a   Baki, Andrea ^a   Molnár, László ^a   Fischer, János ^a   Keseru, György M ^a  

^a GEDEON RICHTER LTD   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

CB1 receptor; Hit to lead; Pyrrolo 1,2 a quinoxaline; Rimonabant; SAR

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; N [2 OXO 2 (4H PYRROLO[1,2 A]QUINOXALIN 5 YL)ETHYL]CARBOXYLIC ACID AMIDE DERIVATIVE; PYRROLO[1,2 A]QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; COMPUTER SIMULATION; PIPERIDINES; PYRAZOLES; QUINOXALINES; RATS; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 66749173541     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.05.010     Document Type: Article

References (24)

1. Bray G.A. J. Med. Chem. 49 (2006) 4001
2. Di Marzo V., Bifulco M., and De Petrocellis L. Nat. Rev. Drug Disc. 3 (2004) 771
3. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner I. Nature 346 (1990) 561
4. Pagotto U., Vicennati V., and Pasquali R. Ann. Med. 37 (2005) 270
5. Pertwee R.G. Int. J. Obesity 30 (2006) 513
6. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., and Caput D. FEBS Lett. 350 (1994) 240
7. Bellocchio L., Mancini G., Vicennati V., Pasquali R., and Pagotto U. Curr. Opin. Pharmacol. 6 (2006) 586
8. Lin L.S., Lanza Jr. T.J., Jewell J.P., Liu P., Shah S.K., Qi H., Tong X., Wang J., Xu S.S., Fong T.M., Shen C.P., Lao J., Xiao J.C., Shearman L.P., Stribling D.S., Rosko K., Strack A., Marsh D.J., Feng Y., Kumar S., Samuel K., Yin W., Van der Ploeg L.H., Goulet M.T., and Hagmann W.K. J. Med. Chem. 49 (2006) 7584
9. Griffith D.A., Hadcock J.R., Black S.C., Iredale P.A., Carpino P.A., DaSilva-Jardine P., Day R., DiBrino J., Dow R.L., Landis M.S., O'Connor R.E., and Scott D.O. J. Med. Chem. 52 (2009) 234
10. 80 agonist concentration. The final reaction volume was 60 μl and the final DMSO concentration was set to be 0.9%.
11. i values were calculated by the Cheng-Prusoff equation.
12. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Kuhn P., Weis W.I., Kobilka B.K., and Stevens R.C. Science 318 (2007) 1258
13. Thompson J.D., Higgins D.G., and Gibson T.J. Nucleic Acids Res. 22 (1994) 4673
14. Sali A., and Blundell T.L. J. Mol. Biol. 234 (1993) 779
15. Laskowski R.A., MacArthur M.W., Moss D.S., and Thorton J.M. J. Appl. Crystallogr. 26 (1993) 283
16. Vriend G., and Sander C. J. Appl. Crystallogr. 26 (1993) 47
17. maestro, Version 8.5; Schrodinger: New York, NY, 2008.
18. ligprep, Version 2.2; Schrodinger: New York, NY, 2008.
19. glide, Version 5.0; Schrodinger: New York, NY, 2008.
20. Jorgensen W.L., Maxwell D.S., and Tirado-Rives J. J. Am. Chem. Soc. 118 (1996) 11225
21. Hurst D.P., Lynch D.L., Barnett-Norris J., Hyatt S.M., Seltzman H.H., Zhong M., Song Z.H., Nie J., Lewis D., and Reggio P.H. Mol. Pharmacol. 62 (2002) 1274
22. McAllister S.D., Rizvi G., Anavi-Goffer S., Hurst D.P., Barnett-Norris J., Lynch D.L., Reggio P.H., and Abood M.E. J. Med. Chem. 46 (2003) 5139
23. Kapur A., Hurst D.P., Fleischer D., Whitnell R., Thakur G.A., Makriyannis A., Reggio P.H., and Abood M.E. Mol. Pharmacol. 71 (2007) 1512
24. Lin L.S., Ha S., Ball R.G., Tsou N.N., Castonguay L.A., Doss G.A., Fong T.M., Shen C.P., Xiao J.C., Goulet M.T., and Hagmann W.K. J. Med. Chem. 51 (2008) 2108